Overview
The randomized, placebo-controlled multicenter trial is conducted in five centers in China. After screening and obtaining the signed informed consent , the participants are randomly divided into two groups: acupuncture +IVF group and sham acupuncture +IVF group.
Eligibility
Inclusion Criteria:
- Married women aged 25-40;
- Repeated implantation failure for unknown reasons (after 3 or more consecutive cycles of embryo transfer, or cumulative transfer of ≥6 high-quality cleavage embryos or 4 high-quality blastocysts without clinical pregnancy);
- Transplantable Day 3 high-quality frozen embryos or frozen blastocysts (≥3BB);
- Estrogen and progesterone replacement therapy (HRT), endometrial thickness ≥7mm on the day of endometrial transformation.
Exclusion Criteria:
Patients who met any of the following conditions were not included.
- Those who prepare for PGD;
- Recipients of egg donors;
- Chromosomal abnormalities in both or one of the couples (excluding chromosome polymorphism);
- patients with implantation failure due to known embryonic factors;
- Uterine lesions that may affect implantation (including uterine malformation, uterine tuberculosis, history of intrauterine adhesions, submucosal fibroids, adenomyosis, >4cm intramural fibroids)
- Repeated spontaneous abortion (2 or more fetal loss before 28 weeks of gestation);
- Patients with other endocrine diseases, such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes, adrenal disease, etc., and poor control of hormone levels in the last 3 months;
- Clearly diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, etc.;
- Hydrosalpinx untreated;
- BMI less than 18 and higher than 25kg/m2;
- People with previous history of needle sickness;
- Those who had previously participated in this study or had received acupuncture treatment in the past 3 months.
- Any situation that researchers consider inappropriate for participating in this study.